蛋白酶体抑制剂在癌症治疗中的作用  

The Action of Proteasome Inhibitor in the Cancer Treatment

作　　者：崔利[1] 谷潇[1] 时莎[1] 王斯[2] 

机构地区：[1]中国医科大学,临床医学七年制沈阳110001 [2]中国医科大学病原生物学教研室,沈阳110001

出　　处：《医学综述》2010年第9期1319-1321,共3页Medical Recapitulate

摘　　要：蛋白酶体抑制剂对人工培养的细胞具有有效的抗肿瘤活性,通过降解受调控的促生长细胞周期蛋白来诱导肿瘤细胞的凋亡。这种可以选择性地诱导肿瘤细胞凋亡的方法被证明在动物模型以及人体试验中都非常有效。第一个获准临床试验和上市的蛋白酶体抑制剂硼替佐米,在治疗多发性骨髓瘤的患者中获得了较高的总体有效率和完全缓解率,这些显著的临床效果同时也激励着科学工作者们不断地向新的领域研究和探索。Proteasome inhibitor is effective for the anti-neoplastic activity in the artificially cultured cells.It leads to the apoptosis of tumor cells by degrading growth promoting proteins.This method has been justified in animal model and human testing.Bortezomib is the fist permissive drug studied in clinical trials and put into market.It is mainly used to treat multiple myeloma,with the higher total efficiency and complete remission rate.These evident clinical results also encourage the exploration into new fields.

关 键 词：蛋白酶体 蛋白酶体抑制剂 硼替佐米 

分 类 号：R575[医药卫生—消化系统]